CD34+ Stem Cell Selection for Fanconi Anemia Engraftment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing gene-modified hematopoietic stem cells (HSCs) for treating Fanconi anemia (FA) face challenges in achieving high levels of engraftment due to low CD34+ cell yields and purity, particularly in FA patients, impacting the efficacy of manufactured drug products.
Innovation Solution
A method involving the preparation of high-stringency and low-stringency CD34-enriched cell populations from biological samples, transduced with recombinant gene therapy vectors encoding FANC proteins, to enhance therapeutic efficacy in FA patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If high-stringency CD34-enriched cell population is prepared from FA patient samples, then CD34+ cell purity is improved, but CD34+ cell yield is reduced
Solution Approach 1:
The patent divides the CD34+ cell preparation into two separate populations: high-stringency CD34-enriched cells (high purity) and low-stringency CD34-enriched cells (higher yield). Each population is prepared independently using different selection stringency levels, allowing both purity and yield requirements to be met by combining the two populations rather than relying on a single high-purity preparation that would inevitably have low yield.
Solution Approach 2:
The patent combines the high-stringency CD34-enriched cell population and the low-stringency CD34-enriched cell population to create a composite cell product for gene therapy. This merging strategy allows the high-purity cells to provide quality assurance while the higher-yield low-stringency cells compensate for the loss in absolute number, achieving both purity and yield objectives that cannot be met by high-stringency selection alone.
2Quantity of substance
If low-stringency CD34-enriched cell population is prepared, then CD34+ cell yield is improved, but CD34+ cell purity is reduced
Solution Approach 1:
The patent segments the cell preparation process into two distinct pathways with different stringency levels. The low-stringency pathway is specifically designed to maximize CD34+ cell yield, while the high-stringency pathway ensures high purity. By segmenting the process, each pathway can be optimized for its specific purpose without compromising the overall quality of the final combined product.
Solution Approach 2:
The low-stringency CD34-enriched cell population is merged with the high-stringency population to create a balanced cell product. The low-stringency population provides the necessary quantity of CD34+ cells, while the high-stringency population ensures the required purity level, thereby resolving the contradiction between yield and purity through combination.
3Reliability
If CD34+ cell yield and purity are both optimized, then engraftment efficacy is improved, but preparation complexity increases
Solution Approach 1:
The patent segments the CD34+ cell selection process into two parallel pathways with different stringency levels, allowing each pathway to be optimized independently for either yield or purity. This segmentation enables the system to achieve high engraftment efficacy through the combination of both pathways while maintaining manageable preparation complexity through standardized selection protocols.
Solution Approach 2:
The patent utilizes parameter changes in the selection stringency to optimize the cell population characteristics. By adjusting the stringency parameter between the two pathways, the system achieves the desired balance between cell yield and purity, thereby optimizing engraftment efficacy without requiring overly complex preparation procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combined administration of high- and low-stringency CD34-enriched cell populations results in improved therapeutic efficacy, inhibiting disease progression, reversing hematological manifestations, and recovering hematopoietic lineages in FA patients.
Implementation Method 1
ex vivo mediated gene transfer into target cells is a clinically applied method for cell and gene therapy
Implementation Method 2
one or both of the high-stringency CD34-enriched cell population and/or the low-stringency CD34-enriched cell population has been transduced with a recombinant gene therapy vector encoding a FANC polypeptide
Data Source
AI summary
The present invention provides systems and methods for manufacturing and using gene corrected stem cells for gene therapy. In particular, herein provided are methods for treating Fanconi anemia in which a subject's stem cells are selected by a combination of high stringency CD34+ selection and low stringency CD34+ selection, genetically modified using a gene therapy vector encoding a FANC protein or a gene editing system, and administered to the subject.